Terlipressin

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Terlipressin 是一种具有管活性的加压素类似物，也是一种高度选择性的加压素 V1 受体激动剂，可减少内脏血流量和门脉压力并控制急性静脉曲张破裂出血。Terlipressin 具有抗炎和抗氧化作用，可用于肝肾综合征和耐去甲肾上腺素的败血性休克的研究。

Terlipressin is a vasopressin analogue with potent vasoactive properties. Terlipressin is a highly selective vasopressin V1 receptor agonist that reduces the splanchnic blood flow and portal pressure and controls acute variceal bleeding. Terlipressin exerts anti-inflammatory and anti-oxidative effects. Terlipressin has the potential for hepatorenal syndrome and norepinephrine-resistant septic shock research.

Using a mouse nonlethal hepatic ischemia-reperfusion (IR) model, Terlipressin administration significantly ameliorates IR-induced liver apoptosis, necrosis and inflammation.

Terlipressin (25 nM; 24-72 hours; IEC-6 cells) treatment significantly improves cell viability, proliferation and apoptosis in IEC-6 cells. Terlipressin inhibits the secretion of TNF-α and 15-F2t-isoprostane from IEC-6 cells following oxygen and glucose deprivation/re-oxygenation (OGD/R). Terlipressin administration following OGD attenuates OGD/R-induced cell damage via the PI3K signaling pathway.Cell Proliferation Assay Cell Line:IEC-6 cells induced by oxygen and glucose deprivation/re-oxygenation (OGD/R) Concentration:25 nM Incubation Time:24 hours, 48 hours, 72 hours Result:Significantly increased the proliferation of IEC-6 cells.

———

Others

Other Targets

Others

———

———

14636-12-5

1227.37

C52H74N16O15S2

>98% (HPLC)

DMSO : 100 mg/mL (81.48 mM; ultraphonic; )

———

———

(-20℃)

With Ice Pack

≥ 2 years